AbbVie and Genentech Join Federal Cash-Pay Drug Platform TrumpRx

American pharmaceutical companies AbbVie and Roche's Genentech have recently added their branded medications to the federal cash-pay platform known as TrumpRx. This platform, which became operational approximately two months prior to this development, aims to provide a direct-to-consumer option for purchasing prescription drugs.

According to Techtarget.com, the inclusion of these major drug manufacturers signifies an expansion of the TrumpRx platform's offerings. The platform is designed to allow consumers to purchase medications directly, potentially bypassing traditional insurance channels for certain transactions. This model typically involves self-payment, offering a different avenue for drug acquisition.

The addition of products from companies like AbbVie and Genentech, both significant players in the pharmaceutical industry, suggests a growing portfolio for TrumpRx. This development is part of an ongoing trend toward exploring alternative drug purchasing and distribution models in the United States.